KaloBios Reports Preliminary Results From Ongoing Phase 1 Study Of KB004

(RTTNews) - KaloBios Pharmaceuticals Inc. (KBIO), Tuesday announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody, which is being developed for hematologic malignancies treatment. The results were presented yesterday at the American Society of Hematology Annual Meeting and Exhibition.

Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study. The experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity. The experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity.

The company said: "As we have not yet reached a maximum tolerated dose, we will continue to study higher doses of KB004 as part of this ongoing trial to determine an optimum high-end dose for the Phase 2 expansion portion of the study in patients with AML or myelodysplastic syndrome (MDS) which is expected to begin by the end of the year."